Carvedilol Ameliorates Low-Turnover Bone Disease in Non-Obese Type 2 Diabetes
Carvedilol Ameliorates Low-Turnover Bone Disease in Non-Obese Type 2 Diabetes
复制标题
DOI：
10.1159/000330853
复制
发表时间：
2011-01-01
影响因子：
4.2
通讯作者：
Fukagawa, Masafumi
中科院分区：
文献类型：
--
作者：
Goto, Shunsuke;Fujii, Hideki;Fukagawa, Masafumi
背景：糖尿病骨病是糖尿病的主要并发症，其特点是骨形成低周转。最近的研究表明，氧化应激可能与糖尿病性骨病有关，而β-肾上腺素能拮抗剂可以增加骨形成。我们的研究调查了具有抗氧化作用的卡维地洛（β-受体阻滞剂）对糖尿病骨病的影响。方法：我们在本研究中使用非肥胖 2 型糖尿病模型自发性糖尿病 Torii (SDT) 大鼠。 Sprague-Dawley 大鼠用作对照（对照，n = 6）。 20周时，SDT大鼠被分为四组：糖尿病组（DM，n = 8）、DM+胰岛素组（DM+I，n = 7）、DM+卡维地洛组（DM+C，n = 8）和DM+N-乙酰半胱氨酸组（DM+N，n = 10）。 30周时处死大鼠，然后评估血液和尿液样本、骨矿物质密度、组织形态计量学和氧化应激。结果：DM+C组和DM+N组骨组织中8-羟基脱氧鸟苷阳性细胞数显着低于DM组。 DM+C和DM+N组的骨面矿物质沉积率和骨形成率均显着高于DM组，且DM+C组优于DM+N组。结论：我们的数据表明，卡维地洛对糖尿病低代谢性骨病具有更强的作用，其作用超出了其抗氧化应激机制。版权所有 (C) 2011 S. Karger AG，巴塞尔
Background: Diabetic bone disease is a major complication in diabetes mellitus and is characterized by low-turnover bone formation. Recent studies have demonstrated that oxidative stress could be associated with diabetic bone disease and that beta-adrenergic antagonists could increase bone formation. Our study investigated the effect of carvedilol (beta-blocker), possessing an antioxidant effect, on diabetic bone disease. Methods: We used the non-obese, type 2 diabetes model Spontaneously Diabetic Torii (SDT) rats in this study. Sprague-Dawley rats were used as controls (control, n = 6). SDT rats were divided into four groups: diabetic (DM, n = 8), DM+insulin (DM+I, n = 7), DM+carvedilol (DM+C, n = 8), and DM+N-acetylcysteine (DM+N, n = 10) at 20 weeks. The rats were sacrificed at 30 weeks, after which blood and urine samples, bone mineral density, histomorphometry, and oxidative stress were evaluated. Results: The number of 8-hydroxydeoxyguanosine-positive cells in bone tissue was significantly lower in the DM+C and DM+N groups than in the DM group. Mineral apposition rate and bone formation rate per bone surface in the DM+C and DM+N groups were significantly higher than those in the DM group, and these parameters were better in the DM+C group than in the DM+N group. Conclusion: Our data suggest that carvedilol has stronger effects on diabetic low-turnover bone disease beyond that which can be attributed to its antioxidative stress mechanism. Copyright (C) 2011 S. Karger AG, Basel